NVCR
NovoCure Limited [NVCR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NVCR Stock Summary
Top NVCR Correlated Resources
NVCR
Top 10 Correlated ETFs
NVCR
Top 10 Correlated Stocks
NVCR
In the News
NVCR Financial details
Company Rating
-
Market Cap
1.45B
Income
-207.04M
Revenue
509.34M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1.45K
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-7.97
Forward P/E
-
PEG
-0.66
P/S
3.12
P/B
3.99
P/C
-
P/FCF
-17.65
Quick Ratio
6.42
Current Ratio
6.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.94
EPS next Y
-
EPS next Q
-
EPS this Y
121.59%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
92.17%
Revenue last 5Y
7.71%
Revenue Q/Q
5.08%
EPS Q/Q
-4.35%
-
-
-
-
SMA20
-19%
SMA50
-37.35%
SMA100
31.52%
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-47%
ROC
-0.23%
Gross Margin
75%
Oper. Margin
-44%
Profit Margin
-39%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.87-83.6
52W High
-75.69%
52W Low
+101.8%
RSI
41.2
Rel Volume
0.64
Avg Volume
1.39M
Volume
890.98K
Perf Week
-8.11%
Perf Month
-25.31%
Perf Quarter
16.45%
Perf Half Y
19.55%
-
-
-
-
Beta
0.432
-
-
Volatility
0.6%, 2.24%
Prev Close
4.78%
Price
20.18
Change
7.17%
Company Profile
- Volume Average 1.39M
- Market Capitalization 1.45B
- Employee 1.45K
- CEO Mr. Asaf Danziger
- Headquarters Saint Helier,JE
- IPO Date 2015-10-01
-
Website
https://www.novocure.com 
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
